ZA200705003B - Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors - Google Patents
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitorsInfo
- Publication number
- ZA200705003B ZA200705003B ZA200705003A ZA200705003A ZA200705003B ZA 200705003 B ZA200705003 B ZA 200705003B ZA 200705003 A ZA200705003 A ZA 200705003A ZA 200705003 A ZA200705003 A ZA 200705003A ZA 200705003 B ZA200705003 B ZA 200705003B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyridinureas
- nicotinamide
- vegf
- growth factor
- vascular endothelial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090420A EP1655297A1 (en) | 2004-11-03 | 2004-11-03 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200705003B true ZA200705003B (en) | 2008-09-25 |
Family
ID=34928841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200705003A ZA200705003B (en) | 2004-11-03 | 2007-06-01 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1655297A1 (xx) |
JP (1) | JP5069119B2 (xx) |
KR (1) | KR20070085609A (xx) |
CN (1) | CN101056870A (xx) |
AU (1) | AU2005300734A1 (xx) |
BR (1) | BRPI0515725A (xx) |
CA (1) | CA2586265C (xx) |
ES (1) | ES2394324T3 (xx) |
IL (1) | IL182335A0 (xx) |
MX (1) | MX2007005340A (xx) |
NO (1) | NO20072803L (xx) |
RU (1) | RU2007120691A (xx) |
WO (1) | WO2006048249A1 (xx) |
ZA (1) | ZA200705003B (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2780A (en) | 2006-10-18 | 2013-09-30 | Pfizer Prod Inc | Biaryl ether urea compounds |
ES2445517T3 (es) * | 2008-08-27 | 2014-03-03 | Leo Pharma A/S | Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa |
HUE043536T2 (hu) | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | PDK1 inhibitorként alkalmazható heterociklusos vegyületek |
US9723840B2 (en) | 2013-11-11 | 2017-08-08 | Syngenta Limited | 1-(pyridazin-3-yl)-imidazolidin-2-one derivatives as herbicides |
JP2017505337A (ja) * | 2014-01-10 | 2017-02-16 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Irak4阻害剤としてのインダゾール化合物 |
KR102392684B1 (ko) | 2014-01-13 | 2022-04-29 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체 |
IL293783B2 (en) | 2017-03-31 | 2024-01-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
PL3704108T3 (pl) | 2017-10-31 | 2024-07-22 | Curis, Inc. | Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego |
CN109942544B (zh) * | 2017-12-21 | 2021-06-11 | 中国科学院合肥物质科学研究院 | 一类新型吲唑类衍生物激酶抑制剂 |
CN108467360B (zh) * | 2018-06-22 | 2021-04-30 | 江苏美迪克化学品有限公司 | 一种阿帕替尼的制备方法及其中间体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
MXPA03010099A (es) * | 2001-05-08 | 2004-03-10 | Schering Ag | Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. |
US7429592B2 (en) * | 2001-05-08 | 2008-09-30 | Schering Aktienegesellschaft | Cyanoanthranilamide derivatives and the use thereof as medicaments |
CN1671666A (zh) * | 2002-07-31 | 2005-09-21 | 舍林股份公司 | Vegfr-2和vegfr-3抑制性的邻氨基苯甲酰胺吡啶化合物 |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
-
2004
- 2004-11-03 EP EP04090420A patent/EP1655297A1/en not_active Withdrawn
-
2005
- 2005-10-28 MX MX2007005340A patent/MX2007005340A/es not_active Application Discontinuation
- 2005-10-28 CN CNA2005800381303A patent/CN101056870A/zh active Pending
- 2005-10-28 ES ES05806225T patent/ES2394324T3/es active Active
- 2005-10-28 WO PCT/EP2005/011709 patent/WO2006048249A1/en active Application Filing
- 2005-10-28 AU AU2005300734A patent/AU2005300734A1/en not_active Abandoned
- 2005-10-28 CA CA2586265A patent/CA2586265C/en not_active Expired - Fee Related
- 2005-10-28 EP EP05806225A patent/EP1807416B1/en active Active
- 2005-10-28 RU RU2007120691/04A patent/RU2007120691A/ru unknown
- 2005-10-28 KR KR1020077012381A patent/KR20070085609A/ko not_active Application Discontinuation
- 2005-10-28 BR BRPI0515725-0A patent/BRPI0515725A/pt not_active IP Right Cessation
- 2005-10-28 JP JP2007538358A patent/JP5069119B2/ja not_active Expired - Fee Related
-
2007
- 2007-03-29 IL IL182335A patent/IL182335A0/en unknown
- 2007-06-01 NO NO20072803A patent/NO20072803L/no not_active Application Discontinuation
- 2007-06-01 ZA ZA200705003A patent/ZA200705003B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005300734A1 (en) | 2006-05-11 |
KR20070085609A (ko) | 2007-08-27 |
WO2006048249A1 (en) | 2006-05-11 |
CA2586265C (en) | 2013-08-06 |
RU2007120691A (ru) | 2008-12-10 |
IL182335A0 (en) | 2007-07-24 |
EP1807416B1 (en) | 2012-08-29 |
EP1807416A1 (en) | 2007-07-18 |
CA2586265A1 (en) | 2006-05-11 |
JP2008518893A (ja) | 2008-06-05 |
NO20072803L (no) | 2007-08-02 |
JP5069119B2 (ja) | 2012-11-07 |
ES2394324T3 (es) | 2013-01-30 |
EP1655297A1 (en) | 2006-05-10 |
CN101056870A (zh) | 2007-10-17 |
BRPI0515725A (pt) | 2008-08-05 |
MX2007005340A (es) | 2007-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200705003B (en) | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | |
IL180325A0 (en) | Fused heterocyclic kinase inhibitors | |
IL198171A0 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
ZA200606683B (en) | Pyrazolotriazines as kinase inhibitors | |
GB2424882B (en) | Selective kinase inhibitors | |
EP1794137A4 (en) | SPECIFIC KINASE INHIBITORS | |
HK1167325A1 (en) | Antibodies against vascular endothelial growth factor receptor-1 -1 | |
ZA200606152B (en) | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors | |
EP1812424A4 (en) | Kinase Inhibitors | |
HK1109403A1 (en) | Anthranilamide pyridinureas as vegf receptor kinase inhibitors | |
PL1763517T3 (pl) | Pochodne pirymidyny jako inhibitory 11BETA-HSD1 | |
ATE520671T1 (de) | Pyrimidin-harnstoff-derivate als kinase-hemmer | |
EP1765336A4 (en) | ANGIOGENESIS INHIBITORS | |
IL187310A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
IL181047A0 (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
ZA200705006B (en) | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | |
ZA200610780B (en) | Fused heterocyclic kinase inhibitors | |
ZA200607648B (en) | Kinase inhibitors | |
ZA200608775B (en) | Monocyclic heterocycles as kinase inhibitors | |
IL188027A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
ZA200703835B (en) | Heterocyclic substituted bisarylurea derivatives as kinase inhibitors | |
ZA200608998B (en) | Imidazole derivatives as tyrosine kinase inhibitors | |
ZA200700923B (en) | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | |
AU2004900103A0 (en) | Selective Kinase Inhibitors |